• 99% Purity Pharmaceutical Raw Powder Gefitinib CAS 184475-35-2
  • 99% Purity Pharmaceutical Raw Powder Gefitinib CAS 184475-35-2
  • 99% Purity Pharmaceutical Raw Powder Gefitinib CAS 184475-35-2
  • 99% Purity Pharmaceutical Raw Powder Gefitinib CAS 184475-35-2
  • 99% Purity Pharmaceutical Raw Powder Gefitinib CAS 184475-35-2
  • 99% Purity Pharmaceutical Raw Powder Gefitinib CAS 184475-35-2

99% Purity Pharmaceutical Raw Powder Gefitinib CAS 184475-35-2

Powder: Yes
Customized: Customized
Certification: GMP, HSE, ISO 9001, USP, BP
Suitable for: Elderly, Adult
State: Solid
Purity: >99%
Samples:
US$ 10/gram 1 gram(Min.Order)
| Request Sample
Customization:
Diamond Member Since 2019

Suppliers with verified business licenses

Rating: 4.9/5

Basic Info.

Model NO.
TGY022019042808
Product Name
Gefitinib
Appearance
White Powder
Specificcation
99%
CAS No.
184475-35-2
Grade
Pharmaceuticals Grade
Shelf Life
2 Years
Storage
Cool Dry Place
Shipping Time
Within 3-7 Working Days
Transport Package
Foil Bag, Box, Drum
Specification
99% min
Trademark
TGY
Origin
China
HS Code
3001200010
Production Capacity
1500kg/Month

Product Description


99% Purity Pharmaceutical Raw Powder Gefitinib CAS 184475-35-2
99% Purity Pharmaceutical Raw Powder Gefitinib CAS 184475-35-2
99% Purity Pharmaceutical Raw Powder Gefitinib CAS 184475-35-2:

Gefitinib is the first selective inhibitor of epidermal growth   factor receptor's (EGFR) tyrosine kinase domain. Thus gefitinib is an EGFR inhibitor. The target protein (EGFR) is a member of a family of receptors (ErbB) which includes Her1(EGFR), Her2(erb-B2), Her3(erb-B3) and Her4 (Erb-B4). EGFR is overexpressed in the cells of certain types of human carcinomas - for example in lung and breast cancers. This leads to inappropriate activation of the anti-apoptotic Ras signalling cascade, eventually leading to uncontrolled cell proliferation. Research on gefitinib-sensitive non-small cell lung cancers has shown that a mutation in the EGFR tyrosine kinase domain is responsible for activating anti-apoptotic pathways.These mutations tend to confer increased sensitivity to tyrosine kinase inhibitors such as gefitinib and erlotinib. Of the types of non-small cell lung cancer histologies, adenocarcinoma is the type that most often harbors these mutations. These mutations are more commonly seen in Asians, women, and non-smokers (who also tend to more often have adenocarcinoma).

Gefitinib inhibits EGFR tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme.Thus the function of the EGFR tyrosine kinase in activating the anti-apoptotic Ras signal transduction cascade is inhibited, and malignant cells are inhibited.



99% Purity Pharmaceutical Raw Powder Gefitinib CAS 184475-35-2
Items of analysis Specification Results
 
 
Appearance
 
 
White to off-white powder
 
 
off-White powder
 
 
Identifcation
 
 
HPLC(RT)
 
 
Complies
 
 
Loss on drying
 
 
≤ 0.5%
 
 
0.13%
 
 
Residue on ignition
 
 
≤0.,1%
 
 
0.1%
 
 
Max Single Impurity
 
 
≤ 0.10 %
 
 
0.09%
 
 
Total Impurity
 
 
≤.1.0%
 
 
0.24%
 
 
Purity(HPLC)
 
 
≥99%
 
 
99.76%
Conclusion Qualified


99% Purity Pharmaceutical Raw Powder Gefitinib CAS 184475-35-2

99% Purity Pharmaceutical Raw Powder Gefitinib CAS 184475-35-2

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

You Might Also Like

Diamond Member Since 2019

Suppliers with verified business licenses

Rating: 4.9/5
Terms of Payment
LC, T/T, D/P, PayPal, Western Union, Small-amount payment
International Commercial Terms(Incoterms)
FOB, CFR, CIF, DAT, FAS, DDP, DAP, CIP, CPT, FCA, EXW, Others